Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002510399 | SCV002819686 | likely pathogenic | Kleefstra syndrome 2 | 2022-12-19 | criteria provided, single submitter | clinical testing | Variant summary: The variant identified by MLPA or other technology involves the deletion of exons 16-38 in the KMT2C gene. A presumed nomenclature of c.(2652+1_2653-1)_(9262+1_9263-1)del has been designated for the purposes of this classification. Although exact breakpoints of this deletion are not known, it is expected to result in a frameshift in the KMT2C gene, a known mechanism of disease. The variant was absent in 21694 control chromosomes (gnomAD, structural variants dataset). To our knowledge, no occurrence of c.(2652+1_2653-1)_(9262+1_9263-1)del in individuals affected with Kleefstra Syndrome 2 and no experimental evidence demonstrating its impact on protein function have been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |